Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effectiveness and safety of upadacitinib for moderate‐to‐severe atopic dermatitis in a real‐world setting: A 52‐week retrospective study
Luigi Gargiulo, Luciano Ibba, Francesco Piscazzi, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 38, Iss. 2
Open Access | Times Cited: 17

Showing 17 citing articles:

Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 4, pp. 919-932
Open Access | Times Cited: 19
Practical Use of Upadacitinib in Patients with Severe Atopic Dermatitis in a Real-World Setting: A Systematic Review
Luciano Ibba, Luigi Gargiulo, Carlo Alberto Vignoli, et al.
Clinical Cosmetic and Investigational Dermatology (2024) Vol. Volume 17, pp. 593-604
Open Access | Times Cited: 8
Sustained Effectiveness of Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A 48-Week Real-World Study
Teppei Hagino, Risa Hamada, Mai Yoshida, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 4, pp. 519-519
Open Access | Times Cited: 6
Drug Survival of Upadacitinib and Predicting Factors of Discontinuation in Adult Patients Affected by Moderate-to-Severe Atopic Dermatitis: An Italian Multicenter Analysis
Elena Pezzolo, Michela Ortoncelli, Silvia Ferrucci, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 2, pp. 553-553
Open Access | Times Cited: 5
Upadacitinib improves symptoms of concomitant allergic rhinitis or allergic asthma in patients with severe atopic dermatitis: A 16‐week multicentre retrospective study
Luigi Gargiulo, Luciano Ibba, Francesco Piscazzi, et al.
Journal of the European Academy of Dermatology and Venereology (2024) Vol. 38, Iss. 9
Closed Access | Times Cited: 5
Upadacitinib 30 mg for the optimal management of moderate-to-severe atopic dermatitis: a 52-week single-center real-world study
Luigi Gargiulo, Luciano Ibba, Matteo Bianco, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 4
Predictive Factors for Long-Term High Responders to Upadacitinib Treatment in Patients with Atopic Dermatitis
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, et al.
Dermatitis (2024)
Closed Access | Times Cited: 4
New and Emerging Biologics and Jak Inhibitors for the Treatment of Prurigo Nodularis: A Narrative Review
M.A. Bianco, F D’Oria, Costanza Falcidia, et al.
Medicina (2025) Vol. 61, Iss. 4, pp. 631-631
Open Access
Effectiveness and Safety of Upadacitinib in Adults Older Than 50 Years With Moderate‐To‐Severe Atopic Dermatitis: A Multicenter Study
Francisco Javier Melgosa Ramos, Lorena Vila Cobreros, Marta Galarreta Pascual, et al.
International Journal of Dermatology (2025)
Closed Access
Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience
Luigi Gargiulo, Luciano Ibba, Carlo Alberto Vignoli, et al.
Journal of Dermatological Treatment (2023) Vol. 34, Iss. 1
Open Access | Times Cited: 9
Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study
Virginia Solitano, Paola Facheris, Magnus Petersen, et al.
Autoimmunity Reviews (2023) Vol. 23, Iss. 3, pp. 103504-103504
Open Access | Times Cited: 7
Early itch relief with upadacitinib predicts later skin clearance in Atopic dermatitis
Teppei Hagino, Mai Yoshida, Risa Hamada, et al.
Journal of Dermatological Treatment (2023) Vol. 35, Iss. 1
Open Access | Times Cited: 6
Comparative efficacy of systemic treatments for atopic dermatitis in adults
Jenna Sesi, Steven R. Feldman
Expert Review of Clinical Immunology (2023) Vol. 20, Iss. 3, pp. 313-320
Closed Access | Times Cited: 4
Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study – il AD (Italian landscape atopic dermatitis)
Luigi Gargiulo, Luciano Ibba, Ângela Alfano, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 1
Effectiveness and Safety of Upadacitinib in Adolescent and Adult Patients with Atopic Dermatitis: An Analysis of Long-Term (Week 52) Data from a Real-World Multicenter Retrospective Review
Brian D. Rankin, Siddhartha Sood, Ye‐Jean Park, et al.
Dermatitis (2024)
Closed Access | Times Cited: 1
Abrocitinib-associated adverse events: a real-world pharmacovigilance study using the FAERS database
Yu Sun, Tao Xu, Suyan Zhu, et al.
Expert Opinion on Drug Safety (2024) Vol. 24, Iss. 2, pp. 233-239
Closed Access
Real-world effectiveness and safety of Janus kinase 1 inhibitors for the treatment of moderate-to-severe atopic dermatitis: a single-center, prospective study in China
Yihui Chen, Qiaozhi Cao, Cong Peng, et al.
Frontiers of Medicine (2024) Vol. 18, Iss. 4, pp. 752-756
Closed Access
Page 1

Scroll to top